Mnemosyne closes on additional $6M in Series A funding

MNEMOSYNE PHARMACEUTICALS INC. closed on an additional $6 million in a Series A financing round, bringing its total Series A funding up to $11.4 million. / COURTESY MNEMOSYNE PHARMACEUTICALS INC.
MNEMOSYNE PHARMACEUTICALS INC. closed on an additional $6 million in a Series A financing round, bringing its total Series A funding up to $11.4 million. / COURTESY MNEMOSYNE PHARMACEUTICALS INC.
PROVIDENCE – Mnemosyne Pharmaceuticals Inc. closed today on an additional $6 million in Series A financing for its drug discovery efforts focused on the identification of new drug treatments for schizophrenia and other neuropsychiatric disorders. The new financing is from Atlas Venture, a Cambridge, Mass., early stage investment firm dedicated to financing disruptive innovation in…
To read the full story, Subscribe or
Subscribe to PBN
- Advertisement -